Specification of the model parameters.

aPharmaceutical Benefits Scheme. Ranibizumab. (Accessed September 2013 from www.pbs.gov.au). 2011.
bA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417–1436.
cThe mean baseline visual acuity of patients in TAP report number 3 is a 50-letter score.
dBressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES et al. (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120: 1443–1454.
AMD: age-related macular degeneration; BCVA: best-corrected visual acuity; CI: confidence interval; CNV: choroidal neovascularization; OC/MC lesion: occult with no classic lesions or minimally classic lesions; PC lesion: predominantly classic lesions; SD: standard deviation; SE: standard error.